Clinical trial
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
NCT00227110 · The University of Texas Health Science Center at San Antonio, Other · Completed
Key facts
| NCT number | NCT00227110 |
|---|---|
| Title | Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) |
| Official title | Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) |
| Lead sponsor | The University of Texas Health Science Center at San Antonio, Other |
| Collaborators | National Institutes of Health (NIH) NIH Takeda Pharmaceuticals North America, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Nonalcoholic Steatohepatitis |
| Intervention type | Drug |
| Interventions | Pioglitazone, Placebo |
| Enrollment | 55 |
| Start date | Oct 1, 2002 |
| Primary completion | Nov 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 27, 2005 |
| Last update posted | Oct 14, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: